Friday 6 November 2026 Export MDGL’s income statement to Excel — free account

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.

Revenue: +50.1%
EPS: +147.3%
Free cash flow: +53.5%
Total debt: +0.45%

Quarter to September 2026, against a year earlier

394.16 5.94 −1.48%

Follow MDGL

Alert me

Market cap: $9.3B
P/E: 0.0×
Fwd P/E: −68.8×
Dividend yield: —
F-score: n/a
Altman Z: 10.48
Beneish M: 0.50
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Madrigal Pharmaceuticals, Inc. (MDGL) Debt to equity

Alert me on Debt to equity

Madrigal Pharmaceuticals, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.5×, down 0.0× from fiscal 2025 (0.6×). Over the past ten years it has ranged from 0.0× (fiscal 2018) to 0.6× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MDGL/debt-to-equity" width="100%" height="360" style="border:0" loading="lazy" title="Madrigal Pharmaceuticals, Inc. debt to equity, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MDGL/metrics/debt-to-equity">Madrigal Pharmaceuticals, Inc. (MDGL) debt to equity — stockrow.com</a></p>

Period	Debt to equity	Change
FY2025	0.6×	261.94%
FY2024	0.2×	(45.31%)
FY2023	0.3×	14.10%
FY2022	0.2×	12,385.00%
FY2021	0.0×	0.00%
FY2020	0.0×	122.22%
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	Debt to equity	Change
Sep 2026	0.5×	(16.35%)
Jun 2026	0.7×	3.91%
Mar 2026	0.6×	11.05%
Dec 2025	0.6×	3.85%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 0.6×

Ten-year median 0.0×

Current reading's percentile 100

Company	Debt to equity
IBRX ImmunityBio, Inc. compare	−0.7×
CYTK Cytokinetics, Incorporated compare	−0.5×
KRYS Krystal Biotech, Inc. compare	0.0×
CAI Caris Life Sciences,�Inc. compare	0.0×
SYRE Spyre Therapeutics, Inc. compare	0.0×
PTGX Protagonist Therapeutics, Inc. compare	0.0×
TWST Twist Bioscience Corporation compare	0.0×
MDGL Madrigal Pharmaceuticals, Inc.	0.5×
TGTX TG Therapeutics, Inc. compare	1.2×
Biotechnology industry median	0.0×
Healthcare sector median	0.0×
Market median	0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

Madrigal Pharmaceuticals, Inc. (MDGL) Debt to equity

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on MDGL

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on MDGL

Stockrow Weekly